Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8081)
All Articles published online
|
Publishing Process of This Article
|
May 26, 2019 (publication date) through Feb 3, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Zhang Y, Chen HM, Liu YM, Peng F, Yu M, Wang WY, Xu H, Wang YS, Lu Y. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report. World J Clin Cases 2019; 7(10): 1221-1229 [PMID: 31183356 DOI: 10.12998/wjcc.v7.i10.1221] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v7/i10/1221.htm |
| Number | Citing Articles |
| 1 |
Surya K. Tripathi, Kamal Pandey, Kannan R. R. Rengasamy, Bijesh K. Biswal. Recent updates on the resistance mechanisms to epidermal growth factor receptor tyrosine kinase inhibitors and resistance reversion strategies in lung cancer. Medicinal Research Reviews 2020; 40(6): 2132 doi: 10.1002/med.21700
|
| 2 |
Jiancheng Qian, Shuohan Zhang, Cheng Jiang. Adverse event profiles of selpercatinib: a real-world pharmacovigilance analysis based on FAERS database. BMC Cancer 2024; 24(1) doi: 10.1186/s12885-024-13250-1
|